Volume 86 Issue 47 | p. 20 | Concentrates
Issue Date: November 24, 2008

AstraZeneca Sells Off Biomanufacturing Plant

Department: Business

AstraZeneca has agreed to divest AstraZeneca Biotech Laboratory, a pilot plant in Södertälje, Sweden, for recombinant proteins and monoclonal antibodies, to Recipharm, a contract development and manufacturing organization. AstraZeneca will hold "a significant minority stake" in the new Recipharm subsidiary, which will supply material for Phase I and II tests of an AstraZeneca drug. AstraZeneca is consolidating all its biotech activities within MedImmune, which it acquired last year.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment